This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The economic analysis considered two main cost categories: study drugs and treatment of complications related to the hepatitis B virus (HBV). The drug-related resource consumption was based on actual dosages administered in the clinical trial. Drug costs were calculated using wholesale acquisition costs. The annual medical costs of disease came from two published studies, which used the reimbursed costs from third-party payers. The costs of out-patient visits and laboratory tests incurred in the clinical trial were excluded from cost estimates, because it was assumed that they would be equivalent in both groups. All costs were in US dollars ($) and a 3% annual discount rate was applied to future costs. The price year was 2006.
Analysis of uncertainty:
A set of univariate sensitivity analyses was carried out for the clinical and economic inputs as well as for the utility valuations. Alternative published sources of data were used together with authors' assumptions. Alternative treatment durations of three, five, and 10 years were also investigated. A comprehensive probabilistic sensitivity analysis was undertaken with 1,000 iterations on two key parameters: viral rebound rates after treatment cessation and the time to the first event.
Results
Entecavir led to a gain of 0.728 QALYs and 0.817 LYs at an incremental cost of $2,350 over lamivudine. Thus, the incremental cost per QALY gained with entecavir was $3,230 (95% confidence interval: $2,312 to $4,528) and the incremental cost per LY gained was $2,877.
The probabilistic sensitivity analysis showed that 99.3% of simulations were below the value of $5,000 per QALY. The most influential model inputs were the efficacy parameters, drug costs, and treatment duration. Increasing the treatment duration increased the cost-utility ratio ($12,233 per QALY at 10 years), but all estimates were well below the threshold of $50,000 per QALY. uncertainty was satisfactorily addressed using both a deterministic and a probabilistic approach. The authors justified their selection of a specific modelling framework, which allowed a better simulation of the disease management. Some potential methodological limitations were pointed out, for example: the possible demographic and clinical differences between the patient samples in the two studies; the paucity of reliable long-term data on the rebound rates after treatment discontinuation; or the appropriateness of extrapolating Chinese data to the US population. The authors pointed out that their analysis referred to patients without co-infections and these findings should be restricted to this specific sub-group of HBV (mono-infected) patients. The authors noted that their results were conservative.
Concluding remarks:
In general, the analysis appears to have been carried out using valid methodology, which makes the authors' conclusions more robust.
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